ATE513903T1 - Herstellung von nahrungsmittel- oder auto-antigen-spezifischen tr1-zellen aus leukozyten oder pbmc - Google Patents

Herstellung von nahrungsmittel- oder auto-antigen-spezifischen tr1-zellen aus leukozyten oder pbmc

Info

Publication number
ATE513903T1
ATE513903T1 AT05291429T AT05291429T ATE513903T1 AT E513903 T1 ATE513903 T1 AT E513903T1 AT 05291429 T AT05291429 T AT 05291429T AT 05291429 T AT05291429 T AT 05291429T AT E513903 T1 ATE513903 T1 AT E513903T1
Authority
AT
Austria
Prior art keywords
auto
pbmc
food
antigen
population
Prior art date
Application number
AT05291429T
Other languages
English (en)
Inventor
Herve Groux
Francoise Cottrez
Arnaud Foussat
Valerie Brun
Original Assignee
Txcell S A
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Txcell S A, Inst Nat Sante Rech Med filed Critical Txcell S A
Application granted granted Critical
Publication of ATE513903T1 publication Critical patent/ATE513903T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4524—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/453—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/53—CD2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/50—Coculture with; Conditioned medium produced by invertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT05291429T 2005-07-01 2005-07-01 Herstellung von nahrungsmittel- oder auto-antigen-spezifischen tr1-zellen aus leukozyten oder pbmc ATE513903T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05291429A EP1739166B1 (de) 2005-07-01 2005-07-01 Herstellung von Nahrungsmittel- oder Auto-Antigen-spezifischen Tr1-Zellen aus Leukozyten oder PBMC

Publications (1)

Publication Number Publication Date
ATE513903T1 true ATE513903T1 (de) 2011-07-15

Family

ID=36168439

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05291429T ATE513903T1 (de) 2005-07-01 2005-07-01 Herstellung von nahrungsmittel- oder auto-antigen-spezifischen tr1-zellen aus leukozyten oder pbmc

Country Status (14)

Country Link
US (1) US7977093B2 (de)
EP (2) EP1739166B1 (de)
JP (2) JP5502322B2 (de)
AT (1) ATE513903T1 (de)
AU (1) AU2006271320B2 (de)
CA (1) CA2613778C (de)
CY (2) CY1112351T1 (de)
DK (2) DK1739166T3 (de)
ES (2) ES2368152T3 (de)
HU (1) HUE029143T2 (de)
PL (2) PL1739166T3 (de)
PT (2) PT1739166E (de)
SI (2) SI1739166T1 (de)
WO (1) WO2007010406A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015989B1 (ru) 2005-08-31 2012-01-30 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Лечение воспалительного заболевания кишечника
ES2595103T3 (es) 2007-10-17 2016-12-27 Txcell Células Tr1, células madre mesenquimales y usos de estas
EP2050814A1 (de) * 2007-10-17 2009-04-22 Txcell Zusammensetzungen zur Behandlung von Multipler Sklerose
EP2062970A1 (de) * 2007-11-26 2009-05-27 Txcell Zusammensetzungen zur Behandlung einer Darmentzündung
DK2113254T3 (da) 2008-04-28 2012-12-03 Txcell Sammensætninger til behandling af en inflammatorisk autoimmun sygdom
EP2113560A1 (de) * 2008-04-28 2009-11-04 TXCell Zusammensetzungen zur Behandlung eines Arthritisleidens
PL2318020T3 (pl) * 2008-06-30 2016-02-29 Univ Heidelberg Immunosupresyjne komórki krwi i sposób ich wytwarzania
GB0820397D0 (en) * 2008-11-07 2008-12-17 Cellerix Sa Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
EP2221364A1 (de) * 2009-02-23 2010-08-25 TXCell Zusammensetzungen zur Behandlung eines allergischen oder asthmatischen Leidens
BR112013023968A2 (pt) 2011-03-25 2016-12-13 Txcell uso de células t reguladoras para a fabricação de medicamentos para tratar condição inflamatória ou autoimune
EP2982746A1 (de) 2014-08-07 2016-02-10 TXCell Regulatorische T-Zellen mit therapeutischem Potenzial
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
EP3633029A4 (de) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation Verfahren zur entwicklung einer natürlichen killerzelle unter verwendung einer t-zelle
TWI832820B (zh) * 2017-07-21 2024-02-21 美商伯克利之光生命科技公司 抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途
AU2019215034C1 (en) 2018-02-01 2022-01-06 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
KR102232321B1 (ko) * 2018-03-23 2021-03-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
US12343397B2 (en) 2018-05-17 2025-07-01 Regents Of The University Of Minnesota Drug-resistant immune cells and methods of use thereof
MY199770A (en) 2018-11-14 2023-11-22 Green Cross Lab Cell Corp Method for culturing cord blood-derived natural killer cells using transformed t cells
PL238336B1 (pl) * 2019-08-22 2021-08-09 Gdanski Univ Medyczny Sposób otrzymywania in vitro antygenowo-specyficznych limfocytów T regulatorowych

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0814838B1 (de) * 1995-03-08 2003-05-14 The Scripps Research Institute Antigen präsentierendes system und aktivierung von t-zellen
US6670146B2 (en) * 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
FR2856700B1 (fr) 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
EP1712615A1 (de) * 2005-04-15 2006-10-18 Txcell In vitro Herstellung einer Zellpopulation mittels Nährzellen

Also Published As

Publication number Publication date
US7977093B2 (en) 2011-07-12
WO2007010406A3 (en) 2007-03-29
JP2013240334A (ja) 2013-12-05
CY1117772T1 (el) 2017-05-17
WO2007010406A2 (en) 2007-01-25
PL1739166T3 (pl) 2012-01-31
DK1739166T3 (da) 2011-10-10
JP5502322B2 (ja) 2014-05-28
EP1899459A2 (de) 2008-03-19
PT1739166E (pt) 2011-09-22
EP1899459B1 (de) 2016-03-23
AU2006271320A1 (en) 2007-01-25
EP1739166A1 (de) 2007-01-03
AU2006271320B2 (en) 2012-04-26
CA2613778C (en) 2016-06-07
CY1112351T1 (el) 2015-12-09
CA2613778A1 (en) 2007-01-25
DK1899459T3 (en) 2016-07-18
US20090075372A1 (en) 2009-03-19
EP1739166B1 (de) 2011-06-22
JP2008544760A (ja) 2008-12-11
SI1899459T1 (sl) 2016-09-30
PL1899459T3 (pl) 2016-10-31
SI1739166T1 (sl) 2011-11-30
PT1899459T (pt) 2016-07-08
HUE029143T2 (hu) 2017-02-28
ES2578259T3 (es) 2016-07-22
ES2368152T3 (es) 2011-11-14

Similar Documents

Publication Publication Date Title
HUE029143T2 (hu) Élelmiszer- vagy auto-antigén specifikus TR1 sejtek elõállítása egy leukocita vagy PBMC populációból
Zhu et al. Heterogeneity and plasticity of T helper cells
ATE459652T1 (de) Verfahren zur herstellung von antikörpern
Tanaka et al. Oral CD103− CD11b+ classical dendritic cells present sublingual antigen and induce Foxp3+ regulatory T cells in draining lymph nodes
IL250313B (en) Expansion of renewable stem cell populations
WO2007051038A3 (en) Pdx1-expressing dorsal and ventral foregut endoderm
ISHIKAWA et al. Early cytokine responses during intestinal parasitic infections
BR0302172A (pt) Gama-proteobactéria, e, método para produzir uma substância alvo
ATE514781T1 (de) Nukleinsäuresequenzen, die für proteine in zusammenhang mit abiotischer stressreaktion kodieren, sowie pflanzenzellen und pflanzen mit erhöhter umweltstressverträglichkeit
CL2007003785A1 (es) Acidos nucleicos aislados de bacillus thuringensis, construccion y celulas huesped que comprenden dichos acidos nucleicos, polipeptidos aislados con actividad pesticida codificados por estos polinucleoticos, metodo de produccion de dichas proteinas con actividad pesticida, y para controlar una plaga de insectos.
BRPI0411182A (pt) método para aumentar a toleráncia de uma planta ao estresse abiótico, método para aumentar a biomassa de uma planta, construto de ácido nucléico, polipeptìdio isolado e célula de planta
WO2006108882A8 (en) In vitro production of a cell population using feeder cells
ATE430195T1 (de) Verfahren und zusammensetzungen zur reinigung von nukleinsäure aus einer wirtszelle
RU2008129788A (ru) Улучшенный способ увеличения числа опухоле-реактивных т-лимфоцитов в иммунотерапии онкологических больных
DK1664280T3 (da) Hudregenereringssystem
ATE546464T1 (de) Verfahren zur produktion von rekombinantem protein in cho-zellen
DE60032508D1 (de) VERFAHREN ZUR VERMEHRUNG VON NATüRLICHEN KILLERZELLEN
WO2003020904A3 (en) Methods of generating human cd4+ th1 cells
DK1784486T3 (da) Regenerering af nerver
WO2006026746A3 (en) Methods to separate and expand antigen-specific t cells
ATE544847T1 (de) Verwendung von dendritischen zellen, die interleukin 12 (il-12) exprimieren
CY1107952T1 (el) Δενδριτικα κυτταρα ενεργοποιημενα εν τη παρουσια γλυκοκορτικοειδων ορμονων ειναι ικανα να καταστελλουν αντιγονο-ειδικες αποκρισεις κυτταρων
EP2377922A3 (de) PDX1-exprimierendes Endoderm
ATE485048T1 (de) Pinienzapfenextrakte und ihre verwendung
DE602004029936D1 (de) Schnelles screening-verfahren translationaler fusionspartner zur produktion rekombinanter proteine sowie durch screening damit erhaltene translationale fusionspartner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1739166

Country of ref document: EP